Published in Biochem Biophys Res Commun on May 16, 2003
Engineering building blocks for self-assembling protein nanoparticles. Microb Cell Fact (2010) 0.95
Neuroprotection from NMDA excitotoxic lesion by Cu/Zn superoxide dismutase gene delivery to the postnatal rat brain by a modular protein vector. BMC Neurosci (2006) 0.83
Novel modular transporters delivering anticancer drugs and foreign DNA to the nuclei of target cancer cells. J BUON (2009) 0.79
Comparative analysis of lentiviral vectors and modular protein nanovectors for traumatic brain injury gene therapy. Mol Ther Methods Clin Dev (2014) 0.78
Protein quality in bacterial inclusion bodies. Trends Biotechnol (2006) 2.02
Amyloid-like properties of bacterial inclusion bodies. J Mol Biol (2005) 1.90
Protein folding and conformational stress in microbial cells producing recombinant proteins: a host comparative overview. Microb Cell Fact (2008) 1.89
Aggregation as bacterial inclusion bodies does not imply inactivation of enzymes and fluorescent proteins. Microb Cell Fact (2005) 1.79
Microbial factories for recombinant pharmaceuticals. Microb Cell Fact (2009) 1.59
The conformational quality of insoluble recombinant proteins is enhanced at low growth temperatures. Biotechnol Bioeng (2007) 1.34
Recombinant protein solubility - does more mean better? Nat Biotechnol (2007) 1.21
Localization of functional polypeptides in bacterial inclusion bodies. Appl Environ Microbiol (2006) 1.20
Divergent genetic control of protein solubility and conformational quality in Escherichia coli. J Mol Biol (2007) 1.18
Role of molecular chaperones in inclusion body formation. FEBS Lett (2003) 1.16
Localization of chaperones DnaK and GroEL in bacterial inclusion bodies. J Bacteriol (2005) 1.12
Learning about protein solubility from bacterial inclusion bodies. Microb Cell Fact (2009) 1.09
Nanotechnology, bionanotechnology and microbial cell factories. Microb Cell Fact (2010) 1.09
Biomedical applications of distally controlled magnetic nanoparticles. Trends Biotechnol (2009) 1.08
Bacterial inclusion bodies: making gold from waste. Trends Biotechnol (2011) 1.07
Unconventional microbial systems for the cost-efficient production of high-quality protein therapeutics. Biotechnol Adv (2012) 1.05
Isolation of cell-free bacterial inclusion bodies. Microb Cell Fact (2010) 1.05
Biological role of bacterial inclusion bodies: a model for amyloid aggregation. FEBS J (2011) 1.01
Folding of a misfolding-prone beta-galactosidase in absence of DnaK. Biotechnol Bioeng (2005) 1.01
Side effects of chaperone gene co-expression in recombinant protein production. Microb Cell Fact (2010) 1.01
Tunable geometry of bacterial inclusion bodies as substrate materials for tissue engineering. Nanotechnology (2010) 1.00
Yield, solubility and conformational quality of soluble proteins are not simultaneously favored in recombinant Escherichia coli. Biotechnol Bioeng (2008) 0.99
Nanostructured bacterial materials for innovative medicines. Trends Microbiol (2010) 0.95
Engineering building blocks for self-assembling protein nanoparticles. Microb Cell Fact (2010) 0.95
The chaperone DnaK controls the fractioning of functional protein between soluble and insoluble cell fractions in inclusion body-forming cells. Microb Cell Fact (2006) 0.95
The Functional quality of soluble recombinant polypeptides produced in Escherichia coli is defined by a wide conformational spectrum. Appl Environ Microbiol (2008) 0.94
Membrane-active peptides for non-viral gene therapy: making the safest easier. Trends Biotechnol (2008) 0.91
The nanoscale properties of bacterial inclusion bodies and their effect on mammalian cell proliferation. Biomaterials (2010) 0.90
Systems metabolic engineering, industrial biotechnology and microbial cell factories. Microb Cell Fact (2012) 0.90
Overexpression of the immunoreceptor CD300f has a neuroprotective role in a model of acute brain injury. Brain Pathol (2011) 0.89
Functional inclusion bodies produced in bacteria as naturally occurring nanopills for advanced cell therapies. Adv Mater (2012) 0.89
Modular protein engineering for non-viral gene therapy. Trends Biotechnol (2004) 0.88
Bacterial inclusion bodies are cytotoxic in vivo in absence of functional chaperones DnaK or GroEL. J Biotechnol (2005) 0.87
Protein nanodisk assembling and intracellular trafficking powered by an arginine-rich (R9) peptide. Nanomedicine (Lond) (2010) 0.87
Insertional protein engineering for analytical molecular sensing. Microb Cell Fact (2006) 0.87
Amyloid-linked cellular toxicity triggered by bacterial inclusion bodies. Biochem Biophys Res Commun (2007) 0.87
Peptide-mediated DNA condensation for non-viral gene therapy. Biotechnol Adv (2009) 0.86
Modular protein engineering in emerging cancer therapies. Curr Pharm Des (2009) 0.86
Role of the chaperone DnaK in protein solubility and conformational quality in inclusion body-forming Escherichia coli cells. FEMS Microbiol Lett (2007) 0.86
Influence of growth temperature on the production of antibody Fab fragments in different microbes: a host comparative analysis. Biotechnol Prog (2010) 0.86
Profiling the allosteric response of an engineered beta-galactosidase to its effector, anti-HIV antibody. Biochem Biophys Res Commun (2004) 0.85
Production of functional inclusion bodies in endotoxin-free Escherichia coli. Appl Microbiol Biotechnol (2014) 0.85
Rehosting of bacterial chaperones for high-quality protein production. Appl Environ Microbiol (2009) 0.84
Post-production protein stability: trouble beyond the cell factory. Microb Cell Fact (2011) 0.84
Internalization and kinetics of nuclear migration of protein-only, arginine-rich nanoparticles. Biomaterials (2010) 0.83
In situ protein folding and activation in bacterial inclusion bodies. Biotechnol Bioeng (2008) 0.83
Biological activities of histidine-rich peptides; merging biotechnology and nanomedicine. Microb Cell Fact (2011) 0.83
Fast electrochemical detection of anti-HIV antibodies: coupling allosteric enzymes and disk microelectrode arrays. Anal Chim Acta (2009) 0.83
Lon and ClpP proteases participate in the physiological disintegration of bacterial inclusion bodies. J Biotechnol (2005) 0.83
Integrating mechanical and biological control of cell proliferation through bioinspired multieffector materials. Nanomedicine (Lond) (2015) 0.82
Recombinant protein quality evaluation: proposal for a minimal information standard. Stand Genomic Sci (2011) 0.82
Peptide-assisted traffic engineering for nonviral gene therapy. Drug Discov Today (2008) 0.81
Enhanced response to antibody binding in engineered beta-galactosidase enzymatic sensors. Biochim Biophys Acta (2002) 0.81
Strategies for the production of difficult-to-express full-length eukaryotic proteins using microbial cell factories: production of human alpha-galactosidase A. Appl Microbiol Biotechnol (2015) 0.81
Intracellular CXCR4⁺ cell targeting with T22-empowered protein-only nanoparticles. Int J Nanomedicine (2012) 0.81
DnaK/DnaJ-assisted recombinant protein production in Trichoplusia ni larvae. Appl Microbiol Biotechnol (2009) 0.80
The impact of dnaKJ overexpression on recombinant protein solubility results from antagonistic effects on the control of protein quality. Biotechnol Lett (2004) 0.80
Supramolecular organization of protein-releasing functional amyloids solved in bacterial inclusion bodies. Acta Biomater (2012) 0.80
Interleukin-10 overexpression does not synergize with the neuroprotective action of RGD-containing vectors after postnatal brain excitotoxicity but modulates the main inflammatory cell responses. J Neurosci Res (2011) 0.80
Control of Escherichia coli growth rate through cell density. Microbiol Res (2002) 0.79
High-throughput, functional screening of the anti-HIV-1 humoral response by an enzymatic nanosensor. Mol Immunol (2006) 0.79
Cellular uptake and intracellular fate of protein releasing bacterial amyloids in mammalian cells. Soft Matter (2016) 0.79
Bioadhesiveness and efficient mechanotransduction stimuli synergistically provided by bacterial inclusion bodies as scaffolds for tissue engineering. Nanomedicine (Lond) (2011) 0.79
Analytical approaches for assessing aggregation of protein biopharmaceuticals. Curr Pharm Biotechnol (2011) 0.79
A nanostructured bacterial bioscaffold for the sustained bottom-up delivery of protein drugs. Nanomedicine (Lond) (2013) 0.79
Microbial biofabrication for nanomedicine: biomaterials, nanoparticles and beyond. Nanomedicine (Lond) (2013) 0.79
Nanoparticulate architecture of protein-based artificial viruses is supported by protein-DNA interactions. Nanomedicine (Lond) (2011) 0.79
Bacterial inclusion bodies: an emerging platform for drug delivery and cell therapy. Nanomedicine (Lond) (2012) 0.78
RGD-based cell ligands for cell-targeted drug delivery act as potent trophic factors. Nanomedicine (2012) 0.78
Topographically targeted osteogenesis of mesenchymal stem cells stimulated by inclusion bodies attached to polycaprolactone surfaces. Nanomedicine (Lond) (2013) 0.78
In vivo architectonic stability of fully de novo designed protein-only nanoparticles. ACS Nano (2014) 0.78
Protein aggregation and soluble aggregate formation screened by a fast microdialysis assay. J Biomol Screen (2010) 0.78
Overexpression of the nuclear factor kappaB inhibitor A20 is neurotoxic after an excitotoxic injury to the immature rat brain. Neurol Res (2012) 0.78
Disulfide bond formation and activation of Escherichia coli β-galactosidase under oxidizing conditions. Appl Environ Microbiol (2012) 0.77
Engineering of Escherichia coli beta-galactosidase for solvent display of a functional scFv antibody fragment. FEBS Lett (2003) 0.77
Discriminating foot-and-mouth disease virus-infected and vaccinated animals by use of beta-galactosidase allosteric biosensors. Clin Vaccine Immunol (2009) 0.77
Antiretroviral therapy-induced functional modification of IgG4 and IgM responses in HIV-1-infected individuals screened by an allosteric biosensor. J Biomol Screen (2008) 0.77
Two-dimensional microscale engineering of protein-based nanoparticles for cell guidance. ACS Nano (2013) 0.77
Non-amyloidogenic peptide tags for the regulatable self-assembling of protein-only nanoparticles. Biomaterials (2012) 0.77
Co-production of GroELS discriminates between intrinsic and thermally-induced recombinant protein aggregation during substrate quality control. Microb Cell Fact (2011) 0.77
Screening HIV-1 antigenic peptides as receptors for antibodies and CD4 in allosteric nanosensors. J Mol Recognit (2009) 0.76
Recombinant protein materials for bioengineering and nanomedicine. Nanomedicine (Lond) (2014) 0.76
Engineering the E. coli beta-galactosidase for the screening of antiviral protease inhibitors. Biochem Biophys Res Commun (2005) 0.76
Functionalization of 3D scaffolds with protein-releasing biomaterials for intracellular delivery. J Control Release (2013) 0.76
Engineering protein self-assembling in protein-based nanomedicines for drug delivery and gene therapy. Crit Rev Biotechnol (2013) 0.76
Bacterial inclusion body purification. Methods Mol Biol (2015) 0.76
Inclusion bodies of fuculose-1-phosphate aldolase as stable and reusable biocatalysts. Biotechnol Prog (2012) 0.76
Enhanced molecular recognition signal in allosteric biosensing by proper substrate selection. Biotechnol Bioeng (2006) 0.76
How to break recombinant bacteria: does it matter? Bioeng Bugs (2011) 0.76
A novel bio-functional material based on mammalian cell aggresomes. Appl Microbiol Biotechnol (2015) 0.76
Conformational and functional variants of CD44-targeted protein nanoparticles bio-produced in bacteria. Biofabrication (2016) 0.76
Engineering tumor cell targeting in nanoscale amyloidal materials. Nanotechnology (2016) 0.75
Cross-system excision of chaperone-mediated proteolysis in chaperone-assisted recombinant protein production. Bioeng Bugs (2009) 0.75
Subcutaneous preconditioning increases invasion and metastatic dissemination in mouse colorectal cancer models. Dis Model Mech (2014) 0.75
The scientific impact of microbial cell factories. Microb Cell Fact (2008) 0.75
Improved performance of protein-based recombinant gene therapy vehicles by tuning downstream procedures. Biotechnol Prog (2013) 0.75
Multifunctional nanovesicle-bioactive conjugates prepared by a one-step scalable method using CO2-expanded solvents. Nano Lett (2013) 0.75
Integrated approach to produce a recombinant, His-tagged human α-galactosidase A in mammalian cells. Biotechnol Prog (2011) 0.75
Analysis of recombinant protein toxicity in E. coli through a phage lambda-based genetic screening system. Biotechnol Lett (2007) 0.75